| Literature DB >> 35941586 |
Yingkai Li1, Songyuan He1, Zheng Wu1, Wenzheng Li1, Wen Jian1, Zichao Cheng1, Cong Wang1, Yuchen Shi1, Jinghua Liu2.
Abstract
BACKGROUND: Chronic total occlusion (CTO) of the coronary artery is a difficult problem in clinical practice. The triglyceride-glucose (TyG) index is an effective risk predictor of cardiovascular risk. However, the relationship between the TyG index and the prognosis of CTO patients remains unstudied. Thus, the present study aimed to investigate the relationship between the TyG index and cardiovascular risk in CTO patients.Entities:
Keywords: Cardiovascular events; Chronic total occlusion; Triglyceride-glucose index
Mesh:
Substances:
Year: 2022 PMID: 35941586 PMCID: PMC9361584 DOI: 10.1186/s12933-022-01588-4
Source DB: PubMed Journal: Cardiovasc Diabetol ISSN: 1475-2840 Impact factor: 8.949
Fig. 1Flow diagram of the study. CTO chronic total occlusion, eGFR estimated glomerular filtration rate, MACCEs major adverse cardiac and cerebrovascular events, PCI percutaneous coronary intervention
Baseline characteristics of patients according to TyG index levels
| Variable | Total | TyG index level | |||
|---|---|---|---|---|---|
| T1 | T2 | T3 | |||
| N (%) | 652 | 217 | 223 | 212 | - |
| Age, y | 58.2 ± 10.49 | 59.1 ± 10.78 | 58.5 ± 10.33 | 56.9 ± 10.29 | 0.069 |
| Male, n (%) | 546(83.7) | 189(87.1) | 188(84.3) | 169(79.7) | 0.113 |
| BMI, kg/m2 | 26.0 ± 3.19 | 25.2 ± 3.06 | 26.2 ± 3.06 | 26.7 ± 3.30 | < 0.001 |
| Heart rate, bpm | 72.22 ± 10.60 | 71.11 ± 10.04 | 72.43 ± 11.37 | 73.13 ± 10.26 | 0.133 |
| SBP, mmHg | 128.34 ± 17.32 | 126.41 ± 17.49 | 128.02 ± 17.60 | 130.66 ± 16.66 | 0.037 |
| Medical history and risk factors, n (%) | |||||
| Current smoker | 238(36.5) | 84(38.7) | 75(33.6) | 79(37.3) | 0.522 |
| Hypertension | 431(66.1) | 121(55.8) | 155(69.5) | 155(73.1) | < 0.001 |
| Diabetes | 240(36.8) | 53(24.4) | 71(31.8) | 116(54.7) | < 0.001 |
| Dyslipidemia | 481(73.8) | 153(70.5) | 163(73.1) | 165(77.8) | 0.217 |
| Previous MI | 108(16.6) | 33(15.2) | 39(17.5) | 36(17.0) | 0.797 |
| Previous Stroke | 37(5.7) | 14(6.5) | 17(7.6) | 6(2.8) | 0.081 |
| Previous PCI | 172(26.4) | 61(28.1) | 57(25.6) | 54(25.5) | 0.778 |
| Previous CABG | 32(4.9) | 9(4.1) | 14(6.3) | 9(4.2) | 0.505 |
| Laboratory Tests | |||||
| eGFR, ml/min/1.73m2 | 126.53 ± 32.44 | 132.30 ± 39.25 | 122.95 ± 25.59 | 124.38 ± 30.49 | 0.005 |
| FBG, mmol/L | 6.16 ± 1.36 | 5.5979 ± 0.93 | 6.0504 ± 1.03 | 6.86 ± 1.69 | < 0.001 |
| TC, mmol/L | 4.01 ± 1.05 | 3.72 ± 0.98 | 3.86 ± 0.86 | 4.45 ± 1.15 | < 0.001 |
| TG, mmol/L | 1.28(0.93, 1.76) | 0.84(0.70, 0.97) | 1.30(1.15, 1.50) | 2.05(1.74, 2.54) | < 0.001 |
| LDL-C, mmol/L | 2.39 ± 0.86 | 2.21 ± 0.85 | 2.33 ± 0.75 | 2.62 ± 0.93 | < 0.001 |
| TyG index | 8.8 ± 0.57 | 8.2 ± 0.25 | 8.7 ± 0.13 | 9.4 ± 0.43 | < 0.001 |
| ACS type, n (%) | |||||
| Unstable angina | 567(87.0) | 185(85.3) | 194(87.0) | 188(88.7) | 0.574 |
| AMI | 78(12.0) | 29(13.4) | 26(11.7) | 23(10.8) | 0.714 |
| Medication at discharge, n (%) | |||||
| Aspirin | 640 (98.2) | 214(98.6) | 219(98.2) | 207(97.6) | 0.752 |
| clopidogrel | 426(65.3) | 142(65.4) | 147(65.9) | 137(64.6) | 0.960 |
| ticagrelor | 226(34.7) | 75(34.6) | 76(34.1) | 75(35.4) | 0.960 |
| statin | 639(98.0) | 214(98.6) | 216(96.9) | 209(98.6) | 0.321 |
| Ezetimibe | 134(20.6) | 37(17.1) | 44(19.7) | 53(25.0) | 0.117 |
| Any antidiabetic agents | 167(25.6) | 31(14.3) | 49(22.0) | 87(41.0) | < 0.001 |
| Angiographic Coronary anatomy, n (%) | |||||
| Any left main disease | 150(23.0) | 53(24.4) | 53(23.8) | 44(20.8) | 0.629 |
| Multivessel disease | 392(60.1) | 125(57.6) | 121(54.3) | 146(68.9) | 0.005 |
| Lesions > 20 mm | 295(45.2) | 81(37.3) | 104(35.3) | 110(51.9) | 0.009 |
| Ostial lesion | 70(10.7) | 28(12.9) | 23(10.3) | 19(9.0) | 0.406 |
| Bifurcation | 20(3.1) | 8(3.7) | 6(2.7) | 6(2.8) | 0.808 |
| Treated vessel, n (%) | |||||
| LM | 61(9.4) | 24(11.1) | 21(9.4) | 16(7.5) | 0.458 |
| LAD | 415(63.7) | 148(68.2) | 141(63.2) | 126(59.4) | 0.166 |
| LCX | 264(40.5) | 96(44.2) | 90(40.4) | 78(36.8) | 0.291 |
| RCA | 316(48.5) | 91(41.9) | 115(51.6) | 110(51.9) | 0.062 |
| Mean stent diameters, mm | 2.9 ± 0.40 | 2.8 ± 0.38 | 2.9 ± 0.38 | 2.9 ± 0.42 | 0.490 |
| Total length of stents, mm | 50(29,71) | 50(28,69.5) | 51(29,71) | 50(20,74) | 0.872 |
| Treatment of CTO lesions, n (%) | |||||
| LAD | 251(38.5) | 92(42.4) | 77(34.5) | 82(38.7) | 0.237 |
| LCX | 186(28.5) | 72(33.2) | 66(29.6) | 48(22.6) | 0.049 |
| RCA | 227(34.8) | 57(26.3) | 84(37.7) | 86(40.6) | 0.004 |
| Successful CTO PCI | 503(77.1) | 169(77.9) | 165(74.0) | 169(79.7) | 0.346 |
| Mean stent diameters at CTO lesion, mm | 2.8 ± 0.38 | 2.8 ± 0.37 | 2.8 ± 0.38 | 2.8 ± 0.40 | 0.340 |
| Total length of stents at CTO lesion, mm | 40(26,66) | 40(28,65) | 38.5(25.25,64.75) | 45(28.5,68) | 0.768 |
TyG index triglyceride-glucose index, BMI body mass index, SBP systolic blood pressure, MI myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, eGFR estimated glomerular filtration rate, FBG fasting blood glucose, HbA1c glycosylated haemoglobin, TC total cholesterol, TG triglyceride, LDL-C low-intensity lipoprotein-cholesterol, ACS acute coronary syndrome, AMI acute myocardial infarction, LM left main coronary artery, LAD left anterior descending artery, LCX left circumflex artery, RCA right coronary artery, CTO chronic total occlusion
Relationship between TyG index and cardiovascular events in CTO patients
| TyG Tertiles | HR (95% CI) | |||
|---|---|---|---|---|
| Unadjusted | Model 1a | Model 2a | Model 3a | |
| T1 | 1 (reference)# | 1 (reference)# | 1 (reference)# | 1 (reference)# |
| T2 | 1.29 (0.67–2.47) | 1.29 (0.67–2.47) | 1.32 (0.69–2.52) | 1.24 (0.65–2.38) |
| T3 | 2.44 (1.35–4.39) | 2.44 (1.35–4.39) | 2.46 (1.37–4.44) | 2.09 (1.14–3.86) |
aThe log-rank test and backward stepwise selection methods in a Cox proportional hazards regression model were performed; Model 1: adjusted for age, sex, BMI; Model 2: Model 1 + current smoker, hypertension, diabetes mellitus, dyslipidemia, previous PCI, previous CABG; Model 3: Model 2 + acute myocardial infarction, FBG, TC, LDL-C, successful CTO treatment, using of statin, ezetimibe, or antidiabetic medication. TyG index tertiles: T1: ≤ 8.50, T2: > 8.50, ≤ 8.95, T3: > 8.95
#P < 0.05
Fig. 2Kaplan–Meier curve of cumulative risk of cardiovascular events according to different TyG index levels. TyG index triglyceride-glucose index
Fig. 3The restricted cubic spline of MACCEs and the TyG index. HR hazard ratio, CI confidence interval, MACCEs major adverse cardiovascular and cerebral events, TyG index triglyceride-glucose index
Sensitivity analysis of the relationship between the TyG index and cardiovascular events stratified by diabetes status and successful or failed CTO PCI
| T1 | T2 | T3 | ||||
|---|---|---|---|---|---|---|
| HR (95%CI) | HR (95%CI) | HR (95%CI) | ||||
| DM# | 1 (reference) | 0.356 | 1.81 (0.68–4.86) | 0.237 | 2.11 (0.74–5.98) | 0.162 |
| Non-DM# | 1 (reference) | 0.040 | 1.01 (0.41–2.51) | 0.979 | 2.35 (1.06–5.20) | 0.036 |
| Successful CTO PCI* | 1 (reference) | 0.013 | 1.33 (0.58–0.04) | 0.495 | 2.69 (1.29–5.60) | 0.008 |
| Failed CTO PCI* | 1 (reference) | 0.373 | 0.52 (0.15–1.79) | 0.299 | 1.32 (0.37–4.67) | 0.672 |
#Adjusted for age, sex, BMI, current smoker, hypertension, dyslipidemia, previous PCI, previous CABG, AMI, FBG, TC, LDL-C, using of statin, ezetimibe, or antidiabetic medication, successful CTO PCI. TyG index Tertiles in diabetes mellitus patients: T1: ≤ 8.65, T2: > 8.65, ≤ 9.26, T3: > 9.26; TyG index Tertiles in non-diabetes mellitus patients: T1: ≤ 8.43, T2: > 8.43, ≤ 8.83, T3: > 8.83
*Adjusted for age, sex, BMI, current smoker, hypertension, DM, dyslipidemia, previous PCI, previous CABG, AMI, FBG, TC, LDL-C, using of statin, ezetimibe, or antidiabetic medication. TyG index Tertiles in successful CTO PCI patients: T1: ≤ 8.50, T2: > 8.50, ≤ 8.96, T3: > 8.96; TyG index Tertiles in failed CTO PCI patients: T1: ≤ 8.53, T2: > 8.53, ≤ 8.91, T3: > 8.91